{
    "organizations": [],
    "uuid": "97edcc5ebdd6a004cfcfc7f6158be7e7cb891d5d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ucb-announces-positive-chmp-opinio/brief-ucb-announces-positive-chmp-opinion-for-cimzia-idUSFWN1S41TL",
    "ord_in_thread": 0,
    "title": "BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27 (Reuters) - UCB SA:\n* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS\n* EUROPEAN COMMISSION’S ENDORSEMENT OF CHMP POSITIVE OPINION FOR PSORIASIS EXPECTED IN Q2\n* CHMP POSITIVE OPINION IS BASED ON DATA FROM A PHASE 3 CLINICAL DEVELOPMENT PROGRAM CONSISTING OF CIMPASI-1, CIMPASI-2 AND CIMPACT\n* THIS WOULD FURTHER BROADEN CLINICAL VALUE OF CIMZIA Source text : bit.ly/2JweDGq Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-28T00:17:00.000+03:00",
    "crawled": "2018-04-28T12:33:08.024+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ucb",
        "sa",
        "ucb",
        "announces",
        "positive",
        "chmp",
        "opinion",
        "certolizumab",
        "pegol",
        "patient",
        "plaque",
        "psoriasis",
        "european",
        "commission",
        "endorsement",
        "chmp",
        "positive",
        "opinion",
        "psoriasis",
        "expected",
        "q2",
        "chmp",
        "positive",
        "opinion",
        "based",
        "data",
        "phase",
        "clinical",
        "development",
        "program",
        "consisting",
        "cimpact",
        "would",
        "broaden",
        "clinical",
        "value",
        "cimzia",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}